These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 27628926)
1. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ASSESSMENT OF VASCULAR EFFECTS OCCURRING AFTER AFLIBERCEPT INTRAVITREAL INJECTIONS IN TREATMENT-NAIVE PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION. Mastropasqua L; Toto L; Borrelli E; Carpineto P; Di Antonio L; Mastropasqua R Retina; 2017 Feb; 37(2):247-256. PubMed ID: 27628926 [TBL] [Abstract][Full Text] [Related]
2. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967 [TBL] [Abstract][Full Text] [Related]
3. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY. Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691 [TBL] [Abstract][Full Text] [Related]
4. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Kawasaki R; Sekiryu T; Okada AA; Iida T Am J Ophthalmol; 2015 Apr; 159(4):627-33. PubMed ID: 25555799 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes. Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166 [TBL] [Abstract][Full Text] [Related]
6. Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis. Kim JM; Cho HJ; Kim Y; Jung SH; Lee DW; Kim JW Semin Ophthalmol; 2019; 34(3):168-176. PubMed ID: 31132283 [No Abstract] [Full Text] [Related]
7. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography. Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455 [TBL] [Abstract][Full Text] [Related]
8. Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. Hikichi T; Agarie M Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):1088-1095. PubMed ID: 30901385 [TBL] [Abstract][Full Text] [Related]
9. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105 [TBL] [Abstract][Full Text] [Related]
10. OCT Angiography Features of Neovascularization as Predictive Factors for Frequent Recurrence in Age-Related Macular Degeneration. Choi M; Kim SW; Yun C; Oh J Am J Ophthalmol; 2020 May; 213():109-119. PubMed ID: 31954711 [TBL] [Abstract][Full Text] [Related]
11. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167 [TBL] [Abstract][Full Text] [Related]
12. Initial utilization of aflibercept in exudative age-related macular degeneration. Cho H; Weber ML; Shah CP; Heier JS Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352 [TBL] [Abstract][Full Text] [Related]
13. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration. Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089 [TBL] [Abstract][Full Text] [Related]
14. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT. Miere A; Querques G; Semoun O; Amoroso F; Zambrowski O; Chapron T; Capuano V; Souied EH Retina; 2017 Oct; 37(10):1873-1879. PubMed ID: 28079756 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab. Narayan DS; Muecke J Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334 [TBL] [Abstract][Full Text] [Related]
16. Effect of aflibercept in patients with age-related macular degeneration. Okuma H; Mimura T; Goto M; Kamei Y; Yoshida M; Kondo A; Matsubara M Int Ophthalmol; 2016 Apr; 36(2):159-69. PubMed ID: 26043678 [TBL] [Abstract][Full Text] [Related]
17. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results. de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability. Nomura Y; Yanagi Y Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109 [TBL] [Abstract][Full Text] [Related]
19. Preliminary results of aflibercept in treatment-naive choroidal neovascularization of wet age-related macular degeneration. Gambon R; Barthelmes D; Amstutz C; Fleischhauer J; Kurz-Levin M; Zweifel S Klin Monbl Augenheilkd; 2014 Apr; 231(4):423-6. PubMed ID: 24771183 [TBL] [Abstract][Full Text] [Related]
20. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]